Sorrento Therapeutics (SRNE) is a development stage biopharmaceutical company that offers investors a short-term approval/commercialization opportunity in addition to a long-term investment in the company's innovative drug discovery platform.
Sorrento's lead product candidate, Cynviloq, is poised to enter various Phase III clinical trials for a variety of cancer indications including non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC) and prostate cancer (PC) en route to potential FDA approval via the 505(b)(2) bioequivalence pathway. Cynviloq is a new formulation of the powerful anti-cancer agent Taxol (paclitaxel) and is being developed as a bioequivalent to Celgene's (CELG) Abraxane.
Abraxane, which is human serum albumin-bound paclitaxel, generated sales of $427 million...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: